Mathematical models have been widely used in biology and medicine for several decades, and have, in certain areas, already gained widespread acceptance. We are today in the middle of a major shift in biomedical research: unprecedented and rapidly growing amounts of data from in vitro, in vivo and clinical studies, at molecular, physiological and clinical levels. To make use of these large-scale, multi-level datasets, corresponding multi-level mathematical models are needed, i.e. models that simultaneously capture multiple layers of the biological, physiological and disease-level organisation (also referred to as quantitative systems pharmacology – QSP – models).
In this Research Topic focused on hormone and metabolic research, we would like the contributors to provide overviews of diverse modeling approaches at various levels, from structural biology, signal transduction, to hierarchical whole-body models including the description of long-term disease progression and personalized phenotypes.
Topic Editor Dr. Birgit Schoeberl is employed by Novartis Institutes for BioMedical Research (NIBR). Topic Editor Prof. Pierre de Meyts declares no competing interests with regards to the Research Topic subject.
Mathematical models have been widely used in biology and medicine for several decades, and have, in certain areas, already gained widespread acceptance. We are today in the middle of a major shift in biomedical research: unprecedented and rapidly growing amounts of data from in vitro, in vivo and clinical studies, at molecular, physiological and clinical levels. To make use of these large-scale, multi-level datasets, corresponding multi-level mathematical models are needed, i.e. models that simultaneously capture multiple layers of the biological, physiological and disease-level organisation (also referred to as quantitative systems pharmacology – QSP – models).
In this Research Topic focused on hormone and metabolic research, we would like the contributors to provide overviews of diverse modeling approaches at various levels, from structural biology, signal transduction, to hierarchical whole-body models including the description of long-term disease progression and personalized phenotypes.
Topic Editor Dr. Birgit Schoeberl is employed by Novartis Institutes for BioMedical Research (NIBR). Topic Editor Prof. Pierre de Meyts declares no competing interests with regards to the Research Topic subject.
